Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Arch. endocrinol. metab. (Online) ; 65(2): 172-184, Mar.-Apr. 2021. tab, graf
Article in English | LILACS | ID: biblio-1248817

ABSTRACT

ABSTRACT Objective: Abnormalities involving the TGFB1 gene and its receptors are common in several types of cancer and often related to tumor progression. We investigated the role of single nucleotide polymorphisms (SNP) in the susceptibility to cancer, their impact on its features, as well as the role of mRNA expression of these genes in thyroid malignancy. Materials and methods: We genotyped TGFB1, TGFBR1, and TGFBR2 SNPs in 157 papillary thyroid cancer (PTC) patients and 200 healthy controls. Further, we investigated RNA samples of 47 PTC and 80 benign nodules, searching for differential mRNA expression. Results: SNPs rs1800472 and rs1800469 were associated with characteristics of PTC aggressiveness. Effect predictor software analysis of nonsynonymous SNP rs1800472 indicated increasing protein stability and post-translational changes. TGFB1 mRNA expression was upregulated in PTC and downregulated in benign samples, differentiating malignant from benign nodules (p<0.0001); PTC from goiter (p<0.0001); and PTC from FA (p<0.0001). TGFBR1 mRNA expression was upregulated in goiter and PTC, but downregulated in FA, distinguishing PTC from goiter (p=0.0049); PTC from FA (p<0.0001); and goiter from FA (p=0.0267). On the other hand, TGFBR2 was downregulated in all histological types analyzed and was not able to differentiate thyroid nodules. Conclusion: TGFB1 polymorphism rs1800472 may confer greater activity to TGF-β1 in the tumor microenvironment, favoring PTC aggressiveness. Evaluation of TGFB1 and TGFBR1 mRNA levels may be useful to identify malignancy in thyroid nodules.


Subject(s)
Thyroid Nodule/genetics , Transforming Growth Factor beta1/genetics , Receptor, Transforming Growth Factor-beta Type I/genetics , Receptor, Transforming Growth Factor-beta Type II/genetics , RNA, Messenger/genetics , Thyroid Neoplasms , Polymorphism, Single Nucleotide , Tumor Microenvironment
2.
J. bras. patol. med. lab ; 44(4): 305-308, ago. 2008. ilus
Article in English | LILACS | ID: lil-504213

ABSTRACT

In this study we describe the alterations used to extract and amplify mitochondrial desoxyribonucleic acid (DNA) from formalin-fixed paraffin-embedded samples of canine mammary tumors. The epithelial and mesenchymal components (chondromyxoid and chondroid) of each tumor, as well as the normal mammary gland tissues, were manually microdissected from 19 mixed canine mammary tumors (10 benign mixed tumors and nine carcinomas arising in mixed tumors). DNA was extracted by Invisorb® Spin Tissue Mini Kit, with protocol changes proposed by the manufacturer. A 273-bp fragment was amplified by polymerase chain reaction (PCR) and submitted to automatic sequence analysis. The fragment was successfully analyzed in 100 percent of the samples. However, an additional lysis step, the reduction of volume in buffer solutions and PCR, a higher annealing temperature and an increase in the number of PCR cycles were required. The initial PCR products were diluted and re-amplified in six samples so that they could be successfully analyzed.


A presente comunicação descreve as modificações usadas para extrair e amplificar o DNA mitocondrial obtido de amostras de tumores mamários caninos fixados em formol tamponado a 10 por cento e incluídos em parafina. Os componentes epiteliais e mesenquimais (condromixóide e condróide), bem como a mama normal adjacente, foram microdissectados manualmente de 19 tumores mamários (10 tumores mistos benignos e nove carcinomas em tumores mistos). O DNA foi extraído utilizando-se o Invisorb® Spin Tissue Mini Kit com modificações do protocolo proposto pelo fabricante. Um fragmento de 273-pb foi amplificado por reação em cadeia da polimerase (PCR) e seqüenciado em seqüenciador automático. O fragmento foi analisado em 100 por cento das amostras, entretanto modificações como lise adicional, redução do volume das soluções de extração e PCR, aumento da temperatura de anelamento e do número de ciclos de amplificação foram necessárias. Em seis amostras os produtos iniciais de PCR foram diluídos e reamplificados para obtenção de sucesso.


Subject(s)
Animals , Dogs , Sequence Analysis, DNA/methods , DNA, Mitochondrial/analysis , DNA, Neoplasm/analysis , Breast Neoplasms/genetics , Breast Neoplasms/veterinary , Mixed Tumor, Malignant/genetics , Microdissection/veterinary , Paraffin Embedding , Polymerase Chain Reaction/methods
3.
Arq. bras. endocrinol. metab ; 51(5): 643-653, jul. 2007.
Article in English | LILACS | ID: lil-461339

ABSTRACT

Papillary thyroid carcinoma (PTC) is the most prevalent type of endocrine cancer and, in recent epidemiological surveys, one of the types of human cancer whose incidence is growing. Despite the favourable outcome and long survival rates of most patients, some tumours display an aggressive behaviour and may progress to the highly aggressive and lethal, anaplastic thyroid carcinoma. In recent years, several progresses have been made on the molecular characterization of PTC, in general, and in the genetic alterations underlying the histotype diversity of this type of cancer, in particular. This holds true regarding alterations on nuclear DNA as well as mitochondrial DNA. In this review we have summarized the most recent findings in the genetic characterization of PTC, giving a particular emphasis to the genotype-phenotype associations, the prognosis implications, and the diagnostic and therapeutic value of the newly identified genetic markers.


O carcinoma papilífero de tireóide (CPT) é o tipo mais prevalente de câncer endócrino e, em pesquisas epidemiológicas recentes, um dos tipos de câncer humano cuja incidência vêm crescendo. A despeito do prognóstico favorável e da longa taxa de sobrevivência da maioria dos pacientes, alguns tumores mostram um comportamento agressivo e podem progredir para o altamente agressivo e letal carcinoma anaplásico de tireóide. Recentemente, vários progressos foram feitos quanto à caracterização molecular do CPT, em general, e às alterações genéticas subjacentes à diversidade histológica desse tipo de câncer, em particular, particularmente com respeito às alterações dos DNAs nuclear e mitocondrial. Nesta revisão, nós sumarizamos os achados mais recentes da caracterização genética do CPT, dando ênfase particular às associações genótipo-fenótipo, às implicações prognósticas e ao valor diagnóstico e terapêutico dos marcadores genéticos recentemente identificados.


Subject(s)
Humans , Carcinoma, Papillary/genetics , Thyroid Neoplasms/genetics , Carcinoma, Papillary/diagnosis , Carcinoma, Papillary/therapy , DNA Mutational Analysis , Genotype , Gene Rearrangement/genetics , Genetic Markers/genetics , Molecular Biology , Mutation , Oncogenes , Phenotype , Prognosis , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins c-ret/genetics , Receptor Protein-Tyrosine Kinases/genetics , Receptor, trkA/genetics , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/therapy , ras Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL